Conteltinib (CT-707) is primarily used in the treatment of non-small cell lung cancer (NSCLC), particularly in cases where the cancer is driven by specific genetic alterations, such as ALK (anaplastic lymphoma kinase) rearrangements. It functions as an ALK inhibitor, targeting and blocking the activity of the ALK protein, which is crucial for the growth and survival of cancer cells with these mutations. By inhibiting ALK, Conteltinib helps to slow down or stop the proliferation of cancerous cells, making it a valuable therapeutic option for patients with ALK-positive NSCLC. It is often considered when other ALK inhibitors have failed or are not suitable, providing an alternative treatment pathway for managing advanced or metastatic lung cancer.